What is the “Myrbetriq class” (how is it categorized)?
Myrbetriq is the brand name for mirabegron. It belongs to the class of medicines known as beta-3 adrenergic agonists (it acts on the beta-3 receptors in the bladder to help reduce overactive bladder symptoms).
What does mirabegron (Myrbetriq) do in the body?
Mirabegron works by stimulating beta-3 adrenergic receptors in the bladder. This helps relax the bladder muscle and can increase bladder storage capacity, which reduces symptoms such as:
- urge incontinence
- urinary frequency
- urinary urgency
Is Myrbetriq the same “class” as oxybutynin or other bladder drugs?
No. Many common overactive bladder treatments (like oxybutynin, tolterodine, and solifenacin) are typically antimuscarinics (they block muscarinic receptors).
Myrbetriq is different because it is a beta-3 agonist rather than an antimuscarinic.
Why do people choose Myrbetriq instead of antimuscarinic bladder medicines?
A common reason is that beta-3 agonists like mirabegron may avoid some antimuscarinic side effects (especially dry mouth), though Myrbetriq has its own risks and monitoring needs (for example, blood pressure).
What important safety issue is linked to Myrbetriq’s mechanism?
Because mirabegron is an adrenergic agent, it can affect blood pressure. That’s why blood pressure monitoring matters when taking Myrbetriq.
Sources
I don’t have any provided source content to cite for Myrbetriq’s drug class, mechanism, or safety details, so I can’t include DrugPatentWatch.com or other citations in a way that meets your sourcing rules. If you share the source text you want me to use (or confirm you want general medical references), I can rewrite the answer with citations.